Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circadian Rhythm Impact on Triple Negative Breast Cancer Response to Neoadjuvant Immunotherapy - a Feasibility Randomized Trial

NCT06880029 is registered in ClinicalTrials.gov with Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. as lead sponsor.

NCT NCT06880029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06880029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circadian Rhythm Impact on Triple Negative Breast Cancer Response to Neoadjuvant Immunotherapy - a Feasibility Randomized Trial
Lead sponsor
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 1, 2024
Completion date
September 1, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer (tnbc)